Evidence map›Paper›PMID 33072859›Full record

ArticleAdvanced therapeutics2020

Maltotriose Conjugated Metal-Organic Frameworks for Selective Targeting and Photodynamic Therapy of Triple Negative Breast Cancer Cells and Tumor Associated Macrophages.

Yoshie Sakamaki, John Ozdemir, Alda Diaz Perez, Zachary Heidrick, Olivia Watson, Miu Tsuji, Chirstopher Salmon, Joseph Batta-Mpouma, Anthony Azzun, Valerie Lomonte and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Yoshie SakamakiDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States.
John OzdemirDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Alda Diaz PerezDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Zachary HeidrickDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Olivia WatsonDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Miu TsujiDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Chirstopher SalmonDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Joseph Batta-MpoumaDepartment of Biological and Agricultural Engineering, Institute for Nanoscience and Engineering, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Anthony AzzunDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Valerie LomonteDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Yuchun DuDepartment of Biological Sciences, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Julie StenkenDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States.
Jin Woo-KimDepartment of Biological and Agricultural Engineering, Institute for Nanoscience and Engineering, University of Arkansas, Fayetteville, Arkansas 72701, United States.
M Hassan BeyzaviDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas 72701, United States.
University of Arkansas at Fayetteville · US

Funding

Late-stage [18F]Fluorination: A Tandem Approach for the Synthesis of Positron Emission Tomography (PET) Radiotracers using Metal-Organic Frameworks (MOFs)R15GM132906 · NIGMS · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI BEYZAVI, HUDSON · 2019 to 2019
$428k
NIGMS NIH HHS R15 GM132906
6 · The paper itself

Abstract

Herein, we report a nano-MOF conjugated to maltotriose as a new DDS. MA-PCN-224-0.1Mn/0.9Zn showed its ability to target cancer and TAM. This novel MOF is an effective PDT agent and shows little dark toxicity, MA-PCN-224-0.1Mn/0.9Zn uptakes selectively into cancer cells. A well-suited size control methodology was used so that the nano-scaled MOFs may take advantage of the EPR effect. This development of a nano-scale MOF for PDT that is conjugated to a cancer targeting ligand represents a meaningful development for the use of MOFs as drug delivery systems.

Indexed as

metal-organic framework (MOF)MOFs for Photodynamic Therapypassive and active targetingphotodynamic therapy (PDT)triple-negative breast cancer (TNBC)tumor-associated macrophage (TAM)

Identifiers

PMID33072859
PMCPMC7567337
OpenAlexW3034480412

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.